NIBSC - 19th SoGAT Meeting

Enter a search term

Home Page > Spotlight > Standardisation of Genome Amplification Techniques > Blood virology > Past meetings > 19th SoGAT Meeting

19th SoGAT Meeting

Return to previous page|

June 2006 Presentations

Speaker	Title of Talk	Presentation
Session 1: Progress with standardisation
Gerold Zerlauth, Baxter AG, Austria	SoGAT, mission completed or work in progress?	View Presentation
Roberta Madej, Roche, USA	Progress on study to validate synthetic standards	View Presentation
Kurt Roth, GFE Blut mbH, Germany	Competitive vs. Non-competitive Internal Standards	View Presentation
Sally Baylis, NIBSC	Update on the P. falciparum standard and replacement of the HBV and HCV International Standards	View Presentation
Session 2: Hepatitis B
Junko Tanaka, Hiroshi Yoshizawa, Hiroshima University Graduate School of Biomedical Sciences, Japan	Infectious dose and the concentration of HBV DNA in-vitro	View Presentation
Dominique Challine, INSERM, France	Full-length preS1-preS2-HBs antigen (HBsAg) sequence analysis of HBV surface mutants in HBV DNA-positive organ, tissue and cell donors with various HBV serological profiles	View Presentation
Session 3: NAT assay sensitivity/detection limits and new technology
Michael Chudy, Paul-Ehrlich-Institut, Germany	Analytical and diagnostic sensitivity of HCV NAT tests	View Presentation
Markus Sprenger-Haussels, Qiagen, Germany	Generic automated sample preparation for commercial NAT assays	View Presentation
Lutz Pichl, DRK-Blutspendedienst West and Christine Jork, DRK-Blutspendedienst NSTOB, Germany	One year of experience with Roche´s COBAS AmpliPrep/COBAS TaqMan96 automated PCR system in two large blood bank settings	View Presentation
Martin Stolz, Swiss Blood Transfusion Service, Bern, Switzerland	Evaluation of the Procleix Tigris System at the blood transfusion service SRC Berne	View Presentation
Nico Lelie, Chiron, France	Infectivity based risk modelling	View Presentation
Session 4: EQAS schemes
Elizabeth Dax, NRL, Australia	Ongoing quality control programme for testing for blood-borne pathogens through an internet-based application	View Presentation
Thu-Anh Pham, NRL, Australia	An Internet-based application fostering global collaboration of External Quality Assessment Schemes for Nucleic Acid Testing	View Presentation
Vivienne James, HPA, UK	Update on results of recent EQA panels for blood borne viruses	View Presentation
Micha Nübling, Paul-Ehrlich-Institut, Langen, Germany, Karl-Heinz Buchheit, EDQM, Strasbourg, France	Results from recent EDQM/OMCL PTS studies on B19 DNA NAT testing of plasma pools	View Presentation
Matthias Niedrig, Robert Koch Institut, Germany	First international proficiency study on West Nile virus molecular detection	View Presentation
Session 5: Emerging – re-emerging pathogens
Mike Busch, Blood Systems Research Institute USA	Detection of Dengue Viremia in Blood Donations in Brazil and Honduras	View Presentation
Jean-Pierre Allain, University of Cambridge, UK	GB virus C, West Nile virus, and Dengue virus in West Africa	View Presentation
Session 6: NAT for tissues and organs
Simon Carne, NBS, UK	Strategies for Reducing Inhibition of RT-PCR in cadaveric samples	View Presentation
Theo Cuypers, Sanquin Diagnostic Service, The Netherlands	Validation and one year experience with HCV-RNA and HIV-RNA detection in small test pools on cadaveric samples for viral safety of tissue transplants	View Presentation
Susan L. Stramer, ARC, USA	Testing of Haemopoietic Progenitor Cell (HPC) donors	View Presentation
Session 7: Bacterial screening in blood banks
Theo Cuypers, Sanquin Diagnostic Service, The Netherlands	Experience with detection of bacterial contamination of platelet concentrates with NAT, need for biological standards to compare the efficacy of NAT test protocols	View Presentation
Mark Manak, SeraCare Life Sciences, USA	Controls for blood Septicemia Nucleic Acid Tests	View Presentation
Session 8: Parvoviruses
Kevin Brown, HPA, UK	Overview of parvovirus classification (including detection and seroprevalence of Par 4)	View Presentation
Jacqueline Fryer, NIBSC, UK	Novel and related variant parvoviruses in human plasma	View Presentation
Ewa Brojer, Institute of Haematology and Blood Transfusion, Poland	Level of viremia and genotype characteristics of parvo B19 in blood donors and patients	View Presentation
Marco Koppelman, Sanquin Blood Supply Foundation, The Netherlands	Distributions of Parvo virus B19 genotype 1-3 in plasma donations; need for a genotype panel to standardize quantitative Parvo B19 DNA assays for screening	View Presentation
Mei-ying Yu, CBER FDA	Detection of parvovirus B19 variants in Factor VIII concentrates	View Presentation
Peter Simmonds, Ashleigh Manning, Ed Gomperts and the EADS Group	Persistence/reactivation of parvovirus B19 and newly discovered parvoviruses in haemophiliacs exposed to non-virally inactivated factor VIII concentrates HGDS cohort	View Presentation
Nicola Boschetti, ZLB Behring AG, Switzerland	Parvoviruses: A future challenge	View Presentation
Daniel Candotti, University of Cambridge, UK	Maternofetal transmission on human parvovirus B19 genotype 3	View Presentation
Ruth Laub, CAF-DCF Red Cross, Belgium	Is B19-DNA in donation correlated with virus infectivity?	View Presentation
Sean Doyle, National University of Ireland, Maynooth, Ireland	Parvovirus B19 infection in seronegative and seropositive individuals – implications for blood product safety	View Presentation
Sally Baylis, NIBSC, UK	Primer & Probe Design Affects Ability to Detect and Quantify Variant Viruses	View Presentation
Mike Busch, Blood Systems Research Institute USA	Transmissibility of B19 by transfusion: evaluation of donor viremia prior to performing a linked donor-recipient study	View Presentation
Session 9: Genotypes: HIV and other viruses
Indira Hewlett, FDA, Bethesda, USA	HIV variants and a nanoparticle based assay for detection of HIV-1 p24 and RNA	View Presentation
Richard Myers, UCL Medical School, UK	Analysis of Recombination in the HIV-1 pol Gene	View Presentation
Matthias Gessner, Baxter AG, Austria	What about genotypes? (viral genotypes and their relevance in testing)	View Presentation
Concluding session
Gerold Zerlauth, Baxter Hyland Immuno Ag, Austria	SoGAT, mission completed or work in progress revisited	View Presentation
John Saldanha, Roche, USA	Summing up: NAT testing – where are we heading?	View Presentation

19th SoGAT Meeting

June 2006 Presentations

Speaker

Title of Talk

Presentation